A Feasibility Study on the Identification of Potential Biomarkers in Pulmonary Embolism Using Proteomic Analysis

Fredrik Granholm, MD1, Dan Bylund, PhD2, Ganna Shevchenko, PhD3, Sara B. Lind, PhD3, and Anders E. Henriksson, MD, PhD2,4

Abstract
Acute pulmonary embolism (PE) is a common emergency with a high morbidity and mortality. Most clinical presentations are non-specific and there is a lack of suitable biomarkers for PE. For example, the traditional D-dimer tests show a rather high sensitivity for PE, but yet a rather low positive predictive value due to its lack of specificity. Research on novel biomarkers for PE is thus of interest to improve early diagnostics and reduce the number of unnecessary computed tomography pulmonary angiogram (CTPA) scans performed. In this study we evaluate the feasibility to use label-free quantitative proteomics to discover potential biomarkers for acute PE and to monitor changes in protein levels in PE patients over time. Blood was collected from 8 patients with CTPA verified PE and from 8 patients presenting with same symptoms but with a negative CTPA. The samples were analyzed by liquid chromatography-mass spectrometry and thirteen protein concentrations were found to be significantly changed in PE patients compared to the CTPA negative controls. This exploratory study shows that proteomic analysis can be used to identify potential biomarkers for PE as well as to monitor changes of protein levels over time.

The complement proteins play a part in PE but further studies are needed to clarify their specific role in the pathophysiological process and to look for more specific proteins.

Keywords
pulmonary embolism, biomarker, proteomics, complement factors, venous thromboembolism

Date received: 24 September 2021; revised: 26 November 2021; accepted: 2 January 2022.

Introduction
Acute pulmonary embolism (PE) is a common emergency with a high morbidity and mortality.1 In Sweden the incidence is estimated to be 60/100 000/year and it is increasing with age.2 The clinical presentations are non-specific and the disease often mimic other common diagnoses found in an emergency department (ED).3

Current laboratory tests and biomarkers are not diagnostic for PE but can be used together with decision rules, such as the PERC rule or WELLS score, to alter the clinical suspicion and in this way help physicians in their diagnostic work.4,5 D-dimer tests show a high sensitivity but low specificity for PE. Computed tomography pulmonary angiography (CTPA) is considered as the gold standard in diagnosis of PE, but there is a growing concern related to the radiation risks.6,7 To improve early diagnostics and reduce unnecessary CTPA, novel biomarkers are thus called for. To maximize their usability, these biomarkers need to fulfill at least some of the criteria for an ideal biomarker. For example, the biomarkers should be visible at an early stage, prior to histopathological changes, and be indicative after active damage. Additionally, they should be sensitive, but also correlate with the severity of damage.8 Furthermore, biomarker selection should be driven by an

1 County Hospital of Sundsvall, Sundsvall, Sweden
2 Mid Sweden University, Sundsvall, Sweden
3 Uppsala University, Uppsala, Sweden
4 Sundsvall County Hospital, Sundsvall, Sweden

Corresponding Author:
Fredrik Granholm, Department of Emergency Medicine, County Hospital of Sundsvall, SE-856 43 Sundsvall, Sweden. Email: fredrik.granholm@rvn.se
attempt to answer an explicit clinical question, preferably a causative relationship of the biomarker to disease-state.9

Earlier research regarding new biomarkers in venous thrombembolism (VTE), including PE, has often used blood samples from the post-acute phase when the patient has been started on treatment with anticoagulants. Alternatively, the samples have included patients with deep venous thrombosis (DVT) and PE.10 In the present study we evaluate the feasibility to use proteomic analysis to find suitable, new biomarkers in patients with acute PE. Screening for new biomarkers by a proteomic approach allows a simultaneous detection of changes in multiple proteins in each study.11 It is also a suitable way to monitor changes in protein expression over time. The use of proteomics in this area thereby opens up the possibility to find entirely new biomarkers that traditionally has not been known to have any part in thrombosis or coagulation.

**Methods and Patients**

**Patients**

A total of 16 male patients participated in this study performed at a County Hospital in Sweden, where the ED has about 45 000 annual visits. The patients were all non-smokers without malignancy, and a strictly male patient group was chosen to avoid patients with oral contraceptives and hormone treatment, factors that may affect coagulation and the risk of VTE. Eight of the patients had CTPA verified PE at their visit to the ED and were thus included in the study group. The other eight patients presented similar symptoms as the patients in the study group upon arrival at the ED, but had a negative CTPA and were thereby assigned to a control group. In addition to the initial symptoms, the patients in the study group and the control group were also matched according to cardiovascular risk factors and were all of the same ethnic origin and with similar socio-economic background. The initial symptoms were mainly related to acute onset of dyspnea, cough, chest pain during inspiration and chest pain during rest. Data on current vital signs and routine laboratory tests was gathered from the hospitals electronic medical record, and the basic characteristics of the 16 patients, including age, vital signs, ECG rhythm, D-dimer, Troponin T (TnT) and C-reactive protein (CRP) levels are given in Table 1.

The study was approved by the regional ethics committee, and informed written consent was obtained from all the participants before inclusion.

**Blood Sampling**

Peripheral venous blood samples were taken at the ED from the patients in both groups after CTPA, but before any initiation of anticoagulation treatment. The samples were centrifuged within 30 min at 2000 g for 20 min and aliquots of citrated plasma were frozen and stored at −70°C pending analysis. A follow up blood sample from the patients in the study group was taken at least 12 months after the first one. The same protocols for sampling, sample handling and analysis were applied for these samples.

**Sample Preparation**

**Depletion.** Multiple Affinity Removal System (MARS Hu-14) cartridge was used for depletion of the samples. Prior to depletion, an aliquot of 10 µL of each plasma sample was diluted up to 200 µL with buffer A (Agilent Technologies, Palo Alto, CA, USA). The diluted samples were filtered through 0.22 µm cellulose acetate spin filters (Agilent Technologies) by centrifugation at 15000 × g for 2 min. Afterwards, an aliquot of 190 µL filtered and diluted plasma sample was loaded onto MARS Hu-14 cartridge and the flow-through (FT) fraction was collected by centrifugation for 2 min at 100 × g. Two successive wash steps with 400 µL of Buffer A were carried out to obtain maximum yield. The FT and wash (W) fractions were combined. The spin cartridge was washed with 2 ml of Buffer B (Agilent Technologies) to remove bound proteins and was then re-equilibrated with Buffer A. The remaining fractions (FT + W) were dried using a speed vac.

**Digestion.** The entire amount of protein in each depleted plasma sample was digested with trypsin. Briefly, the proteins were denaturized in 50 µL of digestion buffer (6 M urea, 50 mM ammonium bicarbonate [AmBi]) and sonicated in a sonication bath for 1 min. Afterwards, a volume of 50 µL of 50 mM AmBi was added to all samples. The proteins were reduced, alkylated and on-filter digested by trypsin according to a standard operating procedure. The collected peptide filtrate was vacuum centrifuged to dryness using a speedvac system. Dried peptides were redissolved in 100 µL of 0.1% formic acid and further diluted 6 times prior to nano-LC-MS/MS.

**LC-MS/MS Analysis**

The peptides were separated in reversed-phase on a C18-column with 90 min gradient and electrosprayed on-line to a Q Exactive Plus mass spectrometer (Thermo Finnigan). Tandem mass spectrometry was performed applying HCD.

**Data Analysis**

The 24 RAW-data LC-MS/MS files obtained were quantitatively analysed by the quantification software MaxQuant 1.5.1.2. Proteins were identified by searching towards proteins extracted from Uniprot in November 2018. The search parameters were set to Taxonomy: Homo sapiens, Enzyme: Trypsin, Fixed modification: Carbamidomethyl (C), and Variable modifications: Oxidation (M), Deamidated (NQ). The search criteria for protein identification were set to at least two matching peptides of 95% confidence level per protein.

The results were exported into MS Excel (Microsoft, Redmond, WA, USA) for manual data interpretation and statistical analysis. The most likely biomarkers in the data set were
pin-pointed by a search rule stating that the protein had to be
identified in all 24 samples, that it should show a significant dif-
ference (p < 0.05 according to Welch’s unequal variances t-test) in comparison between study group and control, and also a sig-
nificant change (p < 0.05 according to paired t-test) back
towards the control group level in comparison between acute
and follow-up samples from the study group.

For those proteins fulfilling the above mentioned criteria, a
principal component analysis (PCA) was performed in
MATLAB R2018a (The MathWorks Inc., Natick, MA) to
further illustrate the differences between the samples.

Results
In total, 430 different proteins were tentatively identified in the
data set. Of these, 242 were recovered in quantifiable amounts
in more than one of the samples and 137 were present in all
samples. Nineteen of these 137 plasma proteins showed a sig-
nificant difference in concentration between patients with PE
and matched controls in the acute setting. All of these proteins
tended to be restored towards the control group level for the
follow-up samples from the study group.

Proteins with an Increase in PE Compared with Controls
Complement component 9 was one of the proteins that showed
an increased concentration for the study group. It is a protein
that binds to the assembling membrane attack complex
(MAC). The interaction between the complement system and
hemostatic factors maintain hemostasis under physiologic
conditions as manifested in thrombotic complications of parox-
ysmal nocturnal hemoglobinuria and atypical hemolytic
syndrome.14,15

Another protein that increased in concentration for the PE
patients was Complement factor H, which is also a part of the
complex complement system. Abnormalities of Complement
factor H are associated with thrombotic thrombocytopenic
purpura, hemolytic uremic syndrome and thrombotic
microangiopathy.16,17

The final protein with a marked increase for the study group
compared to the control was Leucine-rich alpha-2-glycoprotein,
which is a type 1 acute phase protein whose expression is upre-
gulated by the mediators of acute-phase response. It has pre-
viously been shown to be involved in angiogenesis.19

Proteins with a Decrease in PE Compared with Controls
Among the proteins that showed decreased concentrations for
the study group, Antithrombin III (AT III), Coagulation factor
XII and Carboxypeptidase B2 have a known part in the path-
ways regulating hemostasis.20–22

AT III is a nonvitamin K-dependent protease that inhibits
coagulation by neutralizing the enzymatic activity of throm-
bin (factors IIa, IXa, Xa).23 Patients with inherited AT III
deficiency have a significantly increased risk of VTE and
are also known to be resistant to anticoagulation by
heparin.24

Studies on Coagulation factor XII show that it may contrib-
ute to the extent of developing thrombus in the intravascular
compartment but also that it has a role in injury repair and
angiogenesis.25

Activated Carboxypeptidase B2 reduces fibrinolysis and the
potential use of carboxypeptidase inhibitors as a new drug treat-
ing VTE is interesting.26

Several proteins found, and described below, are not known
for any specific regulatory role in thrombosis and haemostasis.

Table 1. Basic characteristics of patients in the study (S) and control (C) groups upon arrival to the emergency department.

| Patient ID | Respiratory frequency | Saturation (Air) | Heart rate | ECG rhythm | D-dimer | CRP | TnT |
|------------|-----------------------|------------------|------------|------------|--------|-----|-----|
| S1         | 16                    | 97               | 80         | Sinus      | 1.6    | 5   | 20  |
| S2         | 14                    | 96               | 80         | Sinus      | 0.7    | 45  | <5  |
| S3         | 28                    | 90               | 110        | Sinus      | 4.8    | 17  | 65  |
| S4         | 15                    | 99               | 100        | Sinus      | 0.8    | 23  | -   |
| S5         | 16                    | 100              | 56         | Sinus      | 5.4    | 3   | 8   |
| S6         | 16                    | 99               | 72         | Sinus      | 13     | 40  | 16  |
| S7         | 28                    | 97               | 94         | Sinus      | 5.6    | 6   | 10  |
| S8         | 26                    | 73               | 120        | Sinus      | 5.6    | 78  | 33  |
| C1         | 17                    | 98               | 94         | <0.2       | 2      | 9   |     |
| C2         | 18                    | 100              | 80         | <0.2       | <0.6   | <5  |     |
| C3         | 16                    | 97               | 75         | Sinus      | 0.5    | 14  | <5  |
| C4         | 16                    | 99               | 92         | Sinus      | 0.7    | 5   |     |
| C5         | 20                    | 96               | 89         | Sinus      | 0.8    | 5   | 7   |
| C6         | 16                    | 98               | 68         | Sinus      | –      | 19  | <5  |
| C7         | 28                    | 99               | 82         | Sinus      | 1.7    | <0.6| –   |
| C8         | 20                    | 97               | 70         | Sinus      | 1.3    | 4   | 20  |
Table 2. Label free quantitative (LFQ) data and p-values for the 13 plasma proteins identified as potential biomarkers for pulmonary embolism. The LFQ values represent signal averages for the control group (C) and the study group in the acute (SA) and follow-up samples (SF), while the p-values are obtained from comparisons between the groups with t-tests.

| Protein                                                                 | ID                  | LFQ C | LFQ SA | LFQ SF | p-value SA versus C | p-value SA versus SF |
|------------------------------------------------------------------------|---------------------|-------|--------|--------|---------------------|----------------------|
| Increasing proteins                                                     |                     |       |        |        |                     |                      |
| Complement component 9                                                | A0A024R035          | 0.7E10| 1.1E10 | 0.6E10 | 0.004               | 0.003                |
| Complement factor H                                                   | B2RA39              | 2.7E8 | 4.6E8  | 2.7E8  | 0.027               | 0.033                |
| Leucine-rich α-2-glycoprotein                                         | P02750              | 2.7E9 | 3.9E9  | 1.9E9  | 0.047               | 0.019                |
| Decreasing proteins                                                    |                     |       |        |        |                     |                      |
| Apolipoprotein C-III                                                  | A3KPE2              | 1.5E9 | 0.8E9  | 1.9E9  | 0.047               | 0.035                |
| Carboxylic ester hydrolase                                            | P06776              | 6.6E8 | 4.0E8  | 5.7E8  | 0.027               | 0.037                |
| Antithrombin-III                                                      | A0A024R944          | 4.8E10| 3.1E10 | 4.4E10 | 0.002               | 0.018                |
| Procoagulant C-endopeptidase enhancer                                 | Q15113              | 7.0E7 | 4.6E7  | 6.9E7  | 0.016               | 0.024                |
| Serpin peptidase inhibitor, clade A, member 4                         | B2R815              | 2.4E9 | 1.7E9  | 3.0E9  | 0.030               | 0.000                |
| Carboxypeptidase B2                                                   | A0A087WSY5          | 1.2E9 | 0.8E9  | 1.1E9  | 0.021               | 0.032                |
| Afamin                                                                 | P43652              | 1.7E10| 1.2E10 | 1.7E10 | 0.020               | 0.012                |
| Serpin peptidase inhibitor, clade A, member 5                         | A0A024R6N9          | 5.2E8 | 3.9E8  | 6.6E8  | 0.018               | 0.001                |
| Coagulation factor XII                                                | P00748              | 5.7E9 | 4.4E9  | 6.1E9  | 0.024               | 0.012                |
| N-acetylmuramoyl-L-alanine amidase                                     | Q96PDX              | 2.5E9 | 2.1E9  | 3.1E9  | 0.018               | 0.000                |

Apolipoprotein C-III is secreted by the liver and small intestines and overexpression in humans contribute to atherosclerosis.37

Carboxylic ester hydrolase catalyze the hydrolysis of ester bonds into alcohols and carboxylic acids.28

Procoagulant C-endopeptidase enhancer mediates HDL function by reducing lipid and immune cell accumulation in the artery.29

Serpineptidase inhibitors are part of a family of protease inhibitors. They are central in controlling many proteolytic cascades, including the mammalian coagulation pathways.30

Afamin is a plasma vitamin E-binding glycoprotein primarily expressed in liver and has been found strongly associated with all components of metabolic syndrome.31

N-acetylmuramoyl-L-alanine amidase belongs to a family of hydrolases and proteomic research has suggested that it has a role in differentiating between infectious and non-infectious inflammatory syndromes.32

Discussion

Shortness of breath and chest pain are two very common symptoms for patients presenting in the ED. For the physician it is imperative to at an early stage be able to differentiate and diagnose if these symptoms are due to a myocardial infarction or PE or any other less deadly diagnosis.

An overuse of computed tomography leads to immediate effects with regards to crowding and longer turn over times in an ED.33 And it may also lead to an increase in cancer in otherwise healthy individuals.34

There are currently no reliable biomarkers for early diagnosis of PE. D-dimer can in some cases be used together with a validated scoring system to dismiss the PE diagnosis but an elevated D-dimer test can be found in several other conditions.

As seen in the results many biomarkers are part of the complex systems relating to acute and chronic inflammation as well as coagulation. Numerous previous studies have shown that PE activates coagulation factors as well as inflammatory factors.35 This study unfortunately do not provide final evidence to what comes first, thrombosis or inflammation.

There are several limitations to this study. The number of patients is quite low and the study should be seen as a basis for further research with larger sample size. The fact that it is all male reduces its generalizability to the population as a whole.

In conclusion, this exploratory study shows that it is feasible to use proteomic analysis to look for potential biomarkers in this specific disease and that the complement system and its proteins play a part in acute PE. An interesting observation is that many of the proteins increased or decreased in this study play a part in inflammation and atherosclerosis as well as in hemostasis and thrombus formation. It is therefore possible that the results can be used for further investigations relating to biomarkers in the metabolic syndrome and related diseases.

The findings are currently not clinically applicable and the current method of screening is too slow to influence clinical interventions. However, the results can be used as a basis for future research. Further studies are needed to clarify the protein’s specific role in the pathophysiological process and to look for more specific proteins outside the complement system as well. Additional studies may also clarify the possible role of the proteins from this study in risk stratification, development of prediction rules and treatment strategies with regards to PE.

Acknowledgments

The authors acknowledge the financial support from the Faculty of Science, Technology and Media at Mid Sweden University. The
authors would like to thank Lena Weisby, who participated in the initial planning from a radiological perspective, and Alexander Falk for technical assistance with the LC-MS analysis.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship and/or publication of this article.

ORCID iD
Fredrik Granholm https://orcid.org/0000-0002-1255-8832

References
1. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Respir J. 2020;4(4):543-603.
2. Andersson T, Söderberg S. Incidence of acute pulmonary embolism, related comorbidities and survival: analysis of a Swedish national cohort. BMC Cardiovasc Disord. 2017;17:155:1-7.
3. Corrigan D, Pruncul C, Kabrhel C. Pulmonary embolism: the diagnosis, risk-stratification, treatment and disposition of emergency department patients. Clin Exp Emerg Med. 2016;3(3):117-125.
4. Penaloza A, Verschuren F, Dambrine S, et al. Performance of Pulmonary Embolism Rule-out Criteria (the PERC rule) combined with low clinical probability in high prevalence population. Thromb Res. 2012;129(5):189-193.
5. Wells PS, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients with a probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost. 2000;83(03):416-420.
6. Estrada-Y-Martin RM, Oldham SA. CTPA As the gold standard for diagnosis of pulmonary embolism. Int J CARS. 2011;6(4):557-563.
7. Brenner DJ, Hall EJ. Computed tomography- an increasing source of radiation exposure. N Engl J Med. 1997;337(22):2277-2284.
8. Qualifying Biomarkers. In: Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation. Emerging Safety Science: Workshop Summary. Washington (DC): National Academies Press (US); 2008:65-66.
9. Byrnes SA, Weigl BH. Selecting tomography- an increasing source of radiation exposure. N Engl J Med. 1997;357(22):2277-2284.
10. Qualifying Biomarkers. In: Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation. Emerging Safety Science: Workshop Summary. Washington (DC): National Academies Press (US); 2008:65-66.
11. Bylund D, Henriksson A E. Proteomic approaches to identify circulating biomarkers in patients with abdominal aortic aneurysm. Am J Cardiovasc Dis. 2015;5(3):140-145.
12. Markiewski M M, Nilsson B, Nilsson Ekdahl K, et al. Complement and coagulation: strangers or partners in crime? Trends Immunol. 2007;28(4):184-192.
13. Afshar-Kharghan V. Complement and clot. Blood. 2017;129(16):2214-2215.
14. Risitano AM. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies. In: Lambris J, Holers V, Ricklin D eds. Complement Therapeutics. New York: Springer; 2013:155-172.
15. Peerschke E I, Yin W, Gebrehiwet B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol. 2010;47(13):2170-2175.
16. Rougier N, Kazatchkine MD, Rougier JP, et al. Human complement factor H deficiency associated with hemolytic uremic syndrome. JASN. 1998;9(12):2318-2326.
17. Meri S. Complement activation in diseases presenting with thrombotic microangiopathy. Eur J Intern Med. 2013;24(6):496-502.
18. Serada S, Fujimoto M, Terabe F, et al. Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflamm Bowel Dis. 2012;18(11):2169-2179.
19. Zhang J, Zhu L, Fang J, et al. LRG1 Modulates epithelial-mesenchymal transition and angiogenesis in colorectal cancer via HIF-1α activation. J Exp Clin Cancer Res. 2016;35(29):1-11.
20. Allingstrup M, Wetterslev J, Ravn FB, et al. Antithrombin III for critically ill patients. Cochrane Database Syst Rev. 2016;2:1-2.
21. Leenaerts D, Loyau S, Mertens JC, et al. Carboxypeptidase U (CPU, carboxypeptidase B2, activated thrombin-activatable fibrinolysis inhibitor) inhibition stimulates the fibrinolytic rate in different in vitro models. J Thromb Haemost. 2018;16(10):2057-2069.
22. Coen M, Renné T. Coagulation factor XII in thrombosis and inflammation. Blood. 2018;131(17):1903-1909.
23. Hsu E, Moosavi L. Biochemistry, Antithrombin III. [Updated 2019 Jul 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. https://europepmc.org/article/NBK/NBK545295.
24. Appignani M, Sciartilli A, Caputo M, Di Girolamo E. Successful treatment with rivaroxaban of an extended deep vein thrombosis-complicated by pulmonary embolism in a patient with familial antithrombin III deficiency: a case report. Eur Heart J Case Reports. 2020;4(1):1-5.
25. Stavrou E, Schmaier AH. Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of haemostasis & thrombosis. Thromb Res. 2010;125(3):210-215.
26. Willemse JL, Heylen E, Nesheim ME, et al. Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy? J Thromb Haemost. 2009;7(12):1962-1971.
27. Kanter JE, Shao B, Kramer E, et al. Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes. J Clin Invest. 2019;129(10):4165-4179.
28. Chen Y, Black D S, Reilly PJ. Carboxylic ester hydrolases: classification and database derived from their primary, secondary, and tertiary structures. Protein Sci. 2016 Nov;25(11):1942-1953.
29. Pollard R D, Blesso C N, Zabalawi M, et al. Procollagen C-endopeptidase Enhancer Protein 2 (PCPE2) reduces atherosclerosis in mice by enhancing scavenger receptor class B1
(SR-BI)-mediated high-density lipoprotein (HDL)-cholesteryl ester uptake. *J Biol*. 2015;290(25):15496-15511.

30. Law R HP, Zhang Q, McGowan S, et al. An overview of the Serpin superfamily. *Genome Biol*. 2006;7(216):1-11.

31. Dieplinger H, Dieplinger B. Afamin—A pleiotropic glycoprotein involved in various disease states. *Clin Chim Acta*. 2015;446(June):105-110.

32. Da Silva FP, Regiani Cataldi T, Martins de Lima T, et al. Proteomic profiling identifies N-acetylmuramoyl-l-alanine amidase as a novel biomarker of sepsis. *Biomark Med*. 2016;10(12):1225-1229.

33. Frigini LA, Hoxhaj S, Wintermark M, et al. R-SCAN: CT angiographic imaging for pulmonary embolism. *J Am Coll Radiol*. 2017;14(5):637-640.

34. Sodickson A, Baeyens P, Andriole KP, et al. Recurrent CT, cumulative radiation exposure, and associated radiation-induced cancer risks from CT of adults. *Radiology*. 2009;251-1:175-184.

35. Chirinos J A, Heresi G A, Velasquez H, et al. Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. *J Am Coll Card*. 2005;45(9):1467-1471.